Key result
HTN with T2DM and obesity links to ~59% higher catestatin and worse diastolic dysfunction versus HTN alone.
Why the study?
Arterial hypertension, type 2 diabetes mellitus, and obesity carry a high risk of cardiovascular dysfunction, and catestatin may reflect early cardiac functional abnormalities.
Cross-Sectional (n=270)
No
Absolute Event Rate: 3.3% vs 2.07%
p-value: p=<0.001
Catestatin levels correlate with diastolic dysfunction and metabolic disorders in patients with hypertension, T2DM, and obesity, suggesting its potential utility alongside echocardiography for early heart failure risk stratification.
CST may signal early diastolic dysfunction in cardiometabolic patients; leaves open its value for risk stratification or therapy guidance.
Introduction. Arterial hypertension (AH), type 2 diabetes mellitus (T2DM), and obesity form a cardiometabolic continuum with a high risk of cardiovascular dysfunction. Catestatin (CST) is a promising biomarker of neurohumoral activation and may reflect early cardiac functional abnormalities, especially diastolic dysfunction. The aim of the study. To comprehensively evaluate cardiohemodynamics and catestatin parameters as a possible predictor of cardiovascular dysfunction in patients with hypertension without and with comorbid type 2 diabetes mellitus and obesity. Materials and methods. A total of 250 patients with AH were divided into four groups: isolated AH, AH+obesity, AH+T2DM, and AH+T2DM+obesity; the control group consisted of 20 healthy individuals. Echocardiographic assessment of systolic and diastolic function was performed. Biomarkers including CST, cardiotrophin-1 (CTF-1), β2-microglobulin, glycated hemoglobin (HbA1c), neutrophil gelatinase-associated lipocalin (NGAL), 25-hydroxyvitamin D (25(OH)D), insulin, and leptin were measured. Statistical analysis included univariate and multivariate regression. Results. The most pronounced cardiac remodelling (left ventricular hypertrophy, reduced ejection fraction, impaired filling - early diastolic filling velocity (VE)/late diastolic mitral inflow velocity (VA)<0.7) was observed in the AH+T2DM+obesity group. Elevated CST significantly correlated with HbA1c, CTF-1, β2-microglobulin, and body mass index (BMI) (p<0.05). A logistic regression model was developed to predict CST levels. VE/VA and isovolumic relaxation time (IVRT) showed the significant prognostic value. Conclusions. Catestatin levels correlate with diastolic dysfunction and metabolic disorders in patients with arterial hypertension, type 2 diabetes mellitus, and obesity. Combined catestatin level and echocardiographic assessment improves the early detection and risk stratification of heart failure.
No takes yet. Share an insight, caveat, or question.
Інна Дунаєва (2025) conducted a cross-sectional in Arterial hypertension with or without type 2 diabetes mellitus and obesity (n=270). Comorbid type 2 diabetes mellitus and obesity vs. Isolated arterial hypertension was evaluated on Catestatin (CST) levels (p=<0.001). Patients with arterial hypertension and comorbid type 2 diabetes mellitus and obesity had significantly higher catestatin levels (3.3 vs 2.07 ng/ml) and worse diastolic dysfunction compared to those with isolated hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: